CRL

TentativeAI MemoPost-earnings T+3

Charles River Laboratories International

As of 2026-08-08/Post-earnings T+3/Confidence high

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-08 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence

Action

—

Confidence

high

Horizon

—

Key catalyst

Q2 results and FY2026 guidance raise • 2026-08-05

Base target: $282 / p=55% prob

Biggest risk

RMS remains weak, DSA costs compressed non-GAAP margins, and the GAAP result included a $63.7 million divestiture-related loss. The key risk is that the guidance raise reflects normalization already expected by investors rather than durable acceleration.

Invalidation

Break below $220 or thesis failure.

What would change my mind?

The Q2 print appears better than the packet’s pre-release Zacks estimates of $970.8 million revenue and $2.72 non-GAAP EPS, while the company raised full-year guidance and reported improving DSA demand and a multiyear-high book-to-bill [#PR-EARNINGS-2026-07-30] [#SEC-8K-2026-08-05].

Research note

Recommendation

—

Confidence

high

As of

2026-08-08

Base target

$282

p=55%

Bull target

$315

p=25%

Bear target

$220

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

DSA booking and margin follow-through
RMS weakness and cost execution risk
Portfolio refocus and modernization

BearKey bullets

Divestiture-related losses and portfolio restructuring may continue to distort GAAP earnings and execution.
Higher DSA study-related direct costs and corporate expenses could delay margin recovery.
Post-print analyst coverage remains thin: the available Mizuho target increase retained a Neutral rating, while broader estimate-revision data are unavailable.

WatchKey bullets

Q2 results and FY2026 guidance raise

Summary

High-level snapshot

Recommendation

Model confidence

high

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $282 (p=55%)

Target spread vs base: +12% / -22%

Scenario probabilities

Bull Target: $315 (p=25%)Base Target: $282 (p=55%)Bear Target: $220 (p=20%)

Commentary

The post-earnings tone is positive because Q2 results exceeded the packet’s pre-release framing, guidance increased, and DSA bookings improved. CRL closed at the RankAlpha anchor of $265.51 on August 6 and was quoted at $267.49 on August 7, a modest approximately 0.7% follow-through rather than an outsized repricing. Market reaction was therefore constructive but restrained, while the available analyst revision signal remained mixed. Social sentiment, options skew, short interest, and Glassdoor data are unavailable; this supports cautious monitoring rather than a high-conviction rerating call.

As of 2026-08-08 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

DSA booking and margin follow-through
RMS weakness and cost execution risk
Portfolio refocus and modernization

Scenarios

Bull Target (Scenario probability)

$315 / p=25% prob

Base Target (Scenario probability)

$282 / p=55% prob

Bear Target (Scenario probability)

$220 / p=20% prob

Analysis 2026-08-08 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.72

Social Sentiment (7d)

Events

Other notable items detected

EVENT2026-08-05
Q2 results and FY2026 guidance raise
Q2 revenue was $1.00 billion, non-GAAP EPS was $3.02, organic revenue growth reached 0.1%, and management raised organic revenue guidance by 150 basis points and non-GAAP EPS guidance by $0.25 at the midpoint, citing improving DSA demand and better Manufacturing performance [#SEC-8K-2026-08-05].
Prob 100.00% • Move 4.00% • Priced-in 75.00%

Short-term Catalysts

Next few weeks

DSA booking and margin follow-through
2026-09-30
The highest DSA net book-to-bill in nearly four years and broad-based demand improvement provide near-term support, but investors need evidence that bookings convert into revenue and margins after the guidance raise [#SEC-8K-2026-08-05].
Prob 60% • Move 3% • Priced-in 65%
RMS weakness and cost execution risk
2026-09-30
RMS organic revenue declined 1.4% in Q2, while non-GAAP operating margin fell year over year because of higher DSA study-related direct costs and corporate costs. A renewed demand or margin setback could pressure the raised outlook [#SEC-8K-2026-08-05].
Prob 40% • Move -5% • Priced-in 35%

Long-term Catalysts

Months to a year

Portfolio refocus and modernization
2026-12-31
Completed divestitures, the Lilly TuneLab collaboration, and an AI-enabled digital pathology solution support a more focused regulated-testing portfolio and potential efficiency gains, but financial contribution remains unproven [#SEC-8K-2026-08-05].
Prob 50% • Move 8% • Priced-in 35%

Risks

Divestiture-related losses and portfolio restructuring may continue to distort GAAP earnings and execution.
Higher DSA study-related direct costs and corporate expenses could delay margin recovery.
Post-print analyst coverage remains thin: the available Mizuho target increase retained a Neutral rating, while broader estimate-revision data are unavailable.
RMS demand weakness, especially in North America and research model services.
Recent insider open-market sales are a secondary caution signal, not evidence of operating deterioration [#SEC-FORM4-2026-08-06].
The guidance raise and DSA recovery narrative may already be substantially reflected in the share price.

Peers

Symbol	Summary
ICLR	Direct CRO comparator, though ICON has greater clinical-research exposure and is not a clean match for Charles River’s preclinical and safety-assessment mix.
IQV	Useful strategic and transaction read-through for discovery services and data capabilities, but its larger clinical and technology mix limits valuation comparability.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-08

Loading AI feed…

Symbol

Summary

ICLR

Direct CRO comparator, though ICON has greater clinical-research exposure and is not a clean match for Charles River’s preclinical and safety-assessment mix.

IQV

Useful strategic and transaction read-through for discovery services and data capabilities, but its larger clinical and technology mix limits valuation comparability.